High levels of apolipoprotein B/AI ratio are associated with intracranial atherosclerotic stenosis

Stroke

Volumn 42, Issue 11, 2011, Pages 3040-3046

  Park, Jong Ho ^a   Hong, Keun Sik ^b   Lee, Eun Ja ^a   Lee, Juneyoung ^c   Kim, Dong Eog ^d  

^a Catholic Kwandong University   (South Korea)

^b Inje University   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Dongguk University Ilsan Hospital   (South Korea)

Author keywords

apolipoprotein AI; apolipoprotein B; atherosclerosis; intracranial

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B;

AGED; ARTICLE; BRAIN ATHEROSCLEROSIS; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; EXTRACRANIAL ATHEROSCLEROTIC STENOSIS; FEMALE; HUMAN; INTRACRANIAL ATHEROSCLEROTIC STENOSIS; KOREA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NO CEREBRAL ATHEROSCLEROTIC STENOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STENOSIS;

AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; FEMALE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STROKE;

EID: 80055015449     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.620104     Document Type: Article

References (29)

1. Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Curr Opin Lipidol. 2007;18: 633-637. (Pubitemid 350098568)
2. Walldius G, Jungner I. The ApoB/ApoA-I Ratio: A Strong, New Risk Factor for Cardiovascular Disease and a Target for Lipid-Lowering Therapy-A Review of the Evidence. Blackwell Publishing Ltd; 2006: 493-519.
3. Bielicki JK, Oda MN. Apolipoprotein A-I (Milano) and apolipoprotein A-I (Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry. 2002;41:2089-2096. (Pubitemid 34132283)
4. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004;255:188-205. (Pubitemid 38241363)
5. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA. 2003;290:2292-2300. (Pubitemid 37430562)
6. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361:777-780. (Pubitemid 36293636)
7. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol. 1999;84:28J-32J. (Pubitemid 29334858)
8. Sierra-Johnson J, Somers VK, Kuniyoshi FH, Garza CA, Isley WL, Gami AS, et al. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol. 2006;98: 1369-1373. (Pubitemid 44666643)
9. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol. 2006;26:406-410. (Pubitemid 43732207)
10. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke. 2004;35:2248-2252. (Pubitemid 39311244)
11. Bang OY, Kim JW, Lee JH, Lee MA, Lee PH, Joo IS, et al. Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology. 2005;65:296-298. (Pubitemid 41022378)
12. Bang OY. Intracranial atherosclerotic stroke: specific focus on the metabolic syndrome and inflammation. Curr Atheroscler Rep. 2006;8: 330-336. (Pubitemid 44043652)
13. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1991;325:445-453.
14. Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI. A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol. 2000;21:643-646. (Pubitemid 30210425)
15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. (Pubitemid 41532612)
16. World Health Organization Western Pacific Region; International Association for the Study of Obesity and the International Obesity Task Force. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment Health Communications. Australia Crows Nest, NSW, Australia. 2000.
17. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41. (Pubitemid 23014379)
18. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med. 2006;259:259-266.
19. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2009;265:275-287.
20. Snehalatha C, Vijay V, Suresh Mohan R, Satyavani K, Sivasankari S, Megha T, et al. Lack of association of insulin resistance and carotid intimal medial thickness in non-diabetic Asian Indian subjects. Diabetes Metab Res Rev. 2001;17:444-447. (Pubitemid 34030747)
21. Jadhav UM, Kadam NN. Apolipoproteins: correlation with carotid intima media thickness and coronary artery disease. J Assoc Physicians India. 2004;52:370-375. (Pubitemid 41279747)
22. Bhatia M, Howard SC, Clark TG, Neale R, Qizilbash N, Murphy MF, et al. Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack. Cerebrovasc Dis. 2006;21:323-328. (Pubitemid 44617295)
23. Koren-Morag N, Goldbourt U, Graff E, Tanne D. Apolipoproteins B and AI and the risk of ischemic cerebrovascular events in patients with pre-existing atherothrombotic disease. J Neurol Sci. 2008;270:82-87.
24. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet. 2001;358:2026-2033. (Pubitemid 34084825)
25. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952. (Pubitemid 39208455)
26. Holme I, Aastveit AH, Jungner I, Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2008;264:30-38. (Pubitemid 351813479)
27. Bang OY, Saver JL, Liebeskind DS, Pineda S, Yun SW, Ovbiagele B. Impact of metabolic syndrome on distribution of cervicocephalic atherosclerosis: data from a diverse race-ethnic group. J Neurol Sci. 2009;284: 40-45.
28. D'Armiento FP, Bianchi A, de Nigris F, Capuzzi DM, D'Armiento MR, Crimi G, et al. Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in men without classic risk factors for atherosclerosis. Stroke. 2001;32:2472-2479.
29. Kargman DE, Tuck C, Berglund L, Lin IF, Mukherjee RS, Thompson EV, et al. Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study. Atherosclerosis. 1998;139: 391-399. (Pubitemid 28361825)